Vlado Perkovic
The George Institute for Global Health
Internal medicineUrologySurgeryRenal functionCardiologyRandomized controlled trialIntensive care medicinePlaceboAlbuminuriaType 2 diabetesCanagliflozinKidney diseaseDialysisNephropathyPopulationClinical trialDiabetes mellitusMedicineBlood pressureMeta-analysis
463Publications
93H-index
25kCitations
Publications 458
Newest
#1Hiddo J.L. Heerspink (UG: University of Groningen)H-Index: 70
#2Di XieH-Index: 1
Last. Vlado Perkovic (UNSW: University of New South Wales)H-Index: 93
view all 13 authors...
Background Whether early reduction in albuminuria with atrasentan treatment predicts its longterm kidney protective effect is unknown. Methods To assess long-term effects on kidney outcomes of atrasentan versus placebo in the SONAR trial, we enrolled diabetic patients with chronic kidney disease (stage 2-4) and a urinary albumin creatinine ratio (UACR) of 300 mg/g-5000 mg/g; participants were receiving maximum tolerated renin angiotensin system inhibition. After 6 weeks exposure to 0.75 mg/day a...
1 CitationsSource
#1Kazem RahimiH-Index: 59
#2Zeinab BidelH-Index: 8
Last. Larry AgodoaH-Index: 1
view all 102 authors...
Summary null Background null The effects of pharmacological blood-pressure-lowering on cardiovascular outcomes in individuals aged 70 years and older, particularly when blood pressure is not substantially increased, is uncertain. We compared the effects of blood-pressure-lowering treatment on the risk of major cardiovascular events in groups of patients stratified by age and blood pressure at baseline. null Methods null We did a meta-analysis using individual participant-level data from randomis...
2 CitationsSource
#1Tamara Young (The George Institute for Global Health)H-Index: 4
#2Jingwei Li (The George Institute for Global Health)H-Index: 10
Last. Vlado Perkovic (The George Institute for Global Health)H-Index: 93
view all 14 authors...
Type 2 diabetes mellitus can manifest over a broad clinical range, although there is no clear consensus on the categorisation of disease complexity. We assessed the effects of canagliflozin, compared with placebo, on cardiovascular and kidney outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program over a range of type 2 diabetes mellitus complexity, defined separately by baseline intensity of treatment, duration of diabetes and glycaemic control. We performed a post hoc an...
Source
#1K.Y. Feng (Stanford University)H-Index: 1
#2Jingwei Li (The George Institute for Global Health)H-Index: 10
Last. Bruce Neal (The George Institute for Global Health)H-Index: 116
view all 11 authors...
Aims null To determine the reasons for hospitalizations in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program and the effects of the sodium glucose co-transporter 2 inhibitor canagliflozin on hospitalization. null Materials and methods null A secondary analysis was performed on the CANVAS Program that included 10,142 participants with type 2 diabetes mellitus randomized to canagliflozin or placebo. The primary outcome was total (first plus all recurrent) all-cause hospitalization...
Source
#1Brendon L. Neuen (The George Institute for Global Health)H-Index: 11
#2Megumi Oshima (Kanazawa University)H-Index: 7
Last. José Luis Górriz (University of Valencia)H-Index: 27
view all 19 authors...
Aims null Hyperkalaemia is a common complication of type 2 diabetes mellitus (T2DM) and limits the optimal use of agents that block the renin-angiotensin-aldosterone system, particularly in patients with chronic kidney disease (CKD). In patients with CKD, sodium‒glucose cotransporter 2 (SGLT2) inhibitors provide cardiorenal protection, but whether they affect the risk of hyperkalaemia remains uncertain. null Methods and results null The CREDENCE trial randomized 4401 participants with T2DM and C...
3 CitationsSource
#1Taha Sen (UG: University of Groningen)
#2Jingwei Li (The George Institute for Global Health)H-Index: 10
Last. Yshai Yavin (Janssen Pharmaceutica)H-Index: 4
view all 13 authors...
AIMS/HYPOTHESIS Higher plasma concentrations of tumour necrosis factor receptor (TNFR)-1, TNFR-2 and kidney injury molecule-1 (KIM-1) have been found to be associated with higher risk of kidney failure in individuals with type 2 diabetes in previous studies. Whether drugs can reduce these biomarkers is not well established. We measured these biomarkers in samples of the CANVAS study and examined the effect of the sodium-glucose cotransporter 2 inhibitor canagliflozin on these biomarkers and asse...
Source
#1Hiddo J.L. Heerspink (UMCG: University Medical Center Groningen)H-Index: 70
#2Austin G. Stack (UL: University of Limerick)H-Index: 22
Last. Vlado Perkovic (The George Institute for Global Health)H-Index: 93
view all 11 authors...
Background null Verinurad is a human uric acid transporter (URAT1) inhibitor known to decrease serum uric acid (sUA) levels and may reduce albuminuria. In a Phase 2a study (NCT03118739), treatment with verinurad + febuxostat lowered urine albumin-to-creatinine ratio (UACR) at 12 weeks by 39% (90% confidence interval: 4%, 62%) among patients with type 2 diabetes mellitus, hyperuricaemia and albuminuria. The Phase 2 b, randomised, placebo-controlled Study of verinurAd and alloPurinol in Patients w...
1 CitationsSource
#2Aminu K. Bello (U of A: University of Alberta)H-Index: 41
Last. Sara N. Davison (U of A: University of Alberta)H-Index: 35
view all 45 authors...
Objectives null The Global Kidney Health Atlas (GKHA) is a multinational, cross-sectional survey designed to assess the current capacity for kidney care across all world regions. The 2017 GKHA involved 125 countries and identified significant gaps in oversight, funding and infrastructure to support care for patients with kidney disease, especially in lower-middle-income countries. Here, we report results from the survey for the second iteration of the GKHA conducted in 2018, which included speci...
Source
Background and objectives null Neuropathy is a common complication of kidney disease that lacks proven disease-modifying treatments. Hemodiafiltration improves clearance of uremic toxins and is associated with better nerve function than hemodialysis. We aimed to determine whether hemodiafiltration reduces the progression of neuropathy in people receiving hemodialysis. null Design, setting, participants, & measurements null The Filtration in the Neuropathy of End-Stage Kidney Disease Symptom Evol...
1 CitationsSource
#1Clare Arnott (The George Institute for Global Health)H-Index: 11
#2Jingwei Li (The George Institute for Global Health)H-Index: 10
Last. KW Mahaffey (Janssen Pharmaceutica)H-Index: 4
view all 19 authors...
Heart failure is prevalent in those with type 2 diabetes and chronic kidney disease and is associated with significant mortality and morbidity. In the CREDENCE trial canagliflozin reduced the risk of hospitalization for heart failure (HHF) or cardiovascular (CV) death by 31%. In this current analysis we sought to determine whether the effect of canagliflozin on HHF/CV death differed in subgroups defined by key baseline participant characteristics. Cox regression models were used to estimate haza...
1 CitationsSource